[1] merus announces u.s. fda acceptance and priority review of biologics license application for zeno for the treatment of nrg1+ nsclc and pdac. retrieved may 6, 2024, from https://www.globenewswire.com/news-release/2024/05/06/2876137/37568/en/merus-announces-u-s-fda-acceptance-and-priority-review-of-biologics-license-application-for-zeno-for-the-treatment-of-nrg1-nsclc-and-pdac.html